Dai Han Pharm Co 023910.KQ · KRW

Its shares trade on KOSDAQ under the ticker 023910.KQ. It has been listed since 23 November 1994. In the fiscal year to 31 December 2025, it reported revenue of ₩208.61bn and net income of ₩27.64bn. At that date it held total assets of ₩347.66bn and shareholders' equity of ₩300.21bn.

Daihan Pharmaceutical Co., Ltd. engages in the manufacture and sale of medical products. The company is headquartered in Seoul, Seoul. is a Korea-based company mainly engaged in the manufacture and distribution of pharmaceuticals. The firm provides infusions, including basic infusions, nutritional infusions and infusions for special uses; injections for anesthetics, vitamin-minerals, autonomic nerve systems, hypnotic-sedatives, antispasmodics, antidotes, hormones, analgesics, respiratory and others; contrast media, such as drugs for computed tomography (CT) uses and magnetic resonance imaging (MRI) uses, and other drugs, such as drugs for irrigations, ointments, inhalants, as well as quasi-drugs such as hand gels, lens clean solutions and others.

Figures and description from our data supplier, not checked against the company's own report.

• Dong Yil LeePresident, Director, since 2009
• Yun Wu LeeChief Executive Officer, Director
• Myeong Heok YimInternal Auditor
• Bok Su YumDirector
• Mun Seon LeeNon-Executive Independent Director
• Yeong Gi ChoIR Contact Officer

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.